Pharvaris NV has announced the acceptance of six abstracts for poster presentation at the American Academy of Allergy, Asthma & Immunology (AAAAI) 2026 Annual Meeting, scheduled to take place from February 27 to March 2, 2026, in Philadelphia, PA. Among the data to be presented are pivotal Phase 3 results from the RAPIDe-3 study evaluating deucrictibant for the on-demand treatment of hereditary angioedema $(HAE)$ attacks, as well as final data from the open-label portion of the Phase 2 CHAPTER-1 study assessing deucrictibant for prophylaxis of HAE attacks. Additional presentations will include pharmacokinetic data on an extended-release deucrictibant tablet, findings from a novel kinin biomarker assay, and endpoint validation results. The company noted that the posters and presentation slides will be made available online at the start of each respective presentation. Topline data from the pivotal Phase 3 CHAPTER-3 study of deucrictibant for long-term HAE prophylaxis are anticipated in the third quarter of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharvaris NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9651761-en) on February 10, 2026, and is solely responsible for the information contained therein.